Search Results - "VAN HAL, Gertjan"

Abemaciclib plus fulvestrant in East Asian women with HR+, HER2− advanced breast cancer: Overall survival from MONARCH 2 by Toi, Masakazu, Huang, Chiun‐Sheng, Im, Young‐Hyuck, Sohn, Joohyuk, Zhang, Wei, Sakaguchi, Sachi, Haddad, Nadine, Hal, Gertjan, Sledge, George W.

“…MONARCH 2 is a global, randomized, double‐blind, phase 3 study of abemaciclib/placebo + fulvestrant in patients with hormone receptor positive, human epidermal…”
Get full text

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C β-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer by RADEMAKER-LAKHAI, Jeany M, BEEREPOOT, Laurens V, VAN HAL, Gertjan, BEIJNEN, Jos H, SCHELLENS, Jan H. M, VOEST, Emile E, MEHRA, Niven, RADEMA, Sandra A, VAN MAANEN, Rianne, VERMAAT, Joost S, WITTEVEEN, Els O, VISSEREN-GRUL, Carla M, MUSIB, Luna, ENAS, Nathan

“…Purpose: Enzastaurin targets the protein kinase C and phosphatidylinositol 3-kinase/AKT pathways to reduce tumor angiogenesis and cell proliferation and to…”
Get full text

A randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in participants with relapsed or refractory Ewing sarcoma by VAN HAL, Gertjan, Rubio-San-Simón, Alba, Ogawa, Chitose, Juan-Ribelles, Antonio, Knoderer, Holly, Lewin, Jeremy Howard

“…TPS11580 Background: Ewing’s sarcoma (ES) is the second most common malignant bone tumor affecting children and young adults. Patients with relapsed disease…”
Get full text

Abstract P1-18-21: Abemaciclib plus fulvestrant or nonsteroidal aromatase inhibitor in participants with HR+, HER2- breast cancer - A pooled analysis of the endocrine therapy-naïve participants with measurable disease in MONARCH 2 and MONARCH 3 by Goetz, Matthew P., Trujillo, Jose Luis Gonzalez, Toi, Masakazu, Huober, Jens, Llombart-Cussac, Antonio, Zhang, Wei, Knoderer, Holly, Haddad, Nadine, Van Hal, Gertjan, Sledge, George W.

“…Background: Abemaciclib is an oral selective cyclin dependent kinases 4 & 6 inhibitor (CDK4 & 6i), administered on a continuous schedule. Abemaciclib…”
Get full text

An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer by Lim, Elgene, Boyle, Frances, Okera, Meena, Loi, Sherene, Goksu, Sema Sezgin, van Hal, Gertjan, Chapman, Sonya C., Gable, Jonathon Colby, Chen, Yanyun, Price, Gregory L., Hossain, Anwar M., Gainford, M. Corona, Ezquerra, Meritxell Bellet

“…Purpose Abemaciclib, a CDK4 & 6 inhibitor, is indicated for advanced breast cancer treatment. Diarrhea is a frequently associated adverse event of abemaciclib…”
Get full text

Abstract P5-14-05: The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study by Lim, Elgene, Boyle, Frances, Okera, Meena, Loi, Sherene, Goksu, Sema Sezgin, van Hal, Gertjan, Hartman, Daisy G, Gable, Jonathon Colby, Price, Gregory L, Hossain, Anwar, Gainford, M C, Ezquerra, Meritxell Bellet

“…Background: Abemaciclib is an orally administered inhibitor of cyclin-dependent kinase (CDK) 4/6, dosed twice daily (BID) on a continuous schedule. Diarrhea is…”
Get full text

Abstract PD13-11: PD13-11 Final Overall Survival Analysis of Monarch 2 : A Phase 3 trial of Abemaciclib Plus Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer by Llombart-Cussac, Antonio, Sledge, George, Toi, Masakazu, Neven, Patrick, Sohn, Joo Hyuk, Inoue, Kenichi, Pivot, Xavier, Okera, Meena, Masuda, Norikazu, Kaufman, Peter A., Koh, Han, Grischke, Eva-Maria, Conte, PierFranco, Andre, Valerie, Bian, Yuanyuan, Shahir, Ashwin, van Hal, Gertjan

“…Background Abemaciclib is approved for patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) with progression…”
Get full text

Abstract GS01-12: MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2- advanced breast cancer by Goetz, Matthew, Toi, Masakazu, Huober, Jens, Sohn, Joo Hyuk, Trédan, Olivier, Park, Inhae, Campone, Mario, Chen, Shin-Cheh, Manso, Luis Manual, Paluch-Shimon, Shani, Freedman, Orit C., Andre, Valerie, Saha, Abhijoy, van Hal, Gertjan, Shahir, Ashwin, Iwata, Hiroji, Johnston, Stephen RD, O'Shaughnessy, Joyce, Pivot, Xavier, Tolaney, Sara, Hurvitz, Sara, Llombart, Antonio

“…Background: Abemaciclib is approved both for high-risk early breast cancer as well as advanced breast cancer (ABC) in the first- and second-line setting. In…”
Get full text

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C {szligbeta}-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer by Rademaker-Lakhai, Jeany M, Beerepoot, Laurens V, Mehra, Niven, Radema, Sandra A, van Maanen, Rianne, Vermaat, Joost S, Witteveen, Els O, Visseren-Grul, Carla M, Musib, Luna, Enas, Nathan, van Hal, Gertjan, Beijnen, Jos H, Schellens, Jan HM, Voest, Emile E

“…PURPOSE: Enzastaurin targets the protein kinase C and phosphatidylinositol 3-kinase/AKT pathways to reduce tumor angiogenesis and cell proliferation and to…”
Get full text